The Role and Mechanism of GPER-Hippo-CBS/H2S Pathway in Preeclampsia

Hao Feng

Status: Invitation-only

Conditions: Preeclampsia

Treatments: Other: H2S content

Study type: Interventional

Funder types: Other

Identifiers

NCT06205771

YXLL-KY-2023（031）

Details and patient eligibility

About

The goal of this clinical trial is to learn about in health conditions. The main questions it aims to answer are:

• The pathological significance of GPER in uterine artery dilation in preeclampsia
• The Mechanism of GPER Hippo Pathway Regulating CBS/H2S in Human Uterine Artery Smooth Muscle Cells (hUASMC) This project intends to use GPER interfering RNA, YAP1 interfering RNA, in vivo perfusion experiments of human uterine artery tissue, and single cell patch clamp technology to study hypotheses under physiological/pathological pregnancy conditions at the tissue, cellular, and molecular levels, revealing a novel signal transduction pathway of estrogen stimulating vasodilation, providing new ideas for studying the mechanism of uterine artery blood flow regulation. This research result will provide new targets for intervention and treatment of diseases such as fetal intrauterine growth retardation and preeclampsia.

Full description

1. Measure the content of H2S in uterine arterial smooth muscle and circulation of normal pregnancy and PE pregnant women, and analyze the relationship between the content of H2S in uterine arterial smooth muscle and circulation of PE pregnant women and PE.
2. Knock down the GPER and overexpression of GPER in HTR-8 cells, and detect the expression of GPER, CBS, and Hippo pathway related proteins using Western blot and qRT-PCR to verify the efficiency of knockdown and overexpression. Use different concentrations of H2S donor (GYY4137) to interfere with HTR-8 cells after treatment, and use RT-PCR and Western blot to detect the mRNA and protein expression of downstream molecules YAP and TAZ in Hippo pathway in cells, respectively.

Enrollment: 54 estimated patients

Sex: Female

Ages: Under 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Full term pregnancy with clinical diagnosis of preeclampsia and normal pregnancy pregnant woman
2. Pregnant women undergoing lower segment cesarean section for delivery

Exclusion criteria

1. Combined with chronic hypertension, kidney disease, intrahepatic cholestasis, etc Other basic diseases;
2. Multiple pregnancy
3. Pregnant women undergoing vaginal delivery
4. Normal pregnant women who are<37 weeks or>40 weeks pregnant

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

54 participants in 2 patient groups

NP

No Intervention group

Description:

normal pregnancy and preeclampsia pregnancy

PE

Experimental group

Description:

preeclampsia

Treatment:

Other: H2S content